• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data.

作者信息

Wang Jiasheng, Dasari Srilatha, Elantably Dina, Alkrekshi Akram, Kim Yeseong David

机构信息

Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.

出版信息

Acta Oncol. 2022 Sep;61(9):1157-1161. doi: 10.1080/0284186X.2022.2127121. Epub 2022 Sep 29.

DOI:10.1080/0284186X.2022.2127121
PMID:36173299
Abstract
摘要

相似文献

1
Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data.终末期肾病患者使用PD-1抑制剂：来自真实世界数据的安全性和临床结果
Acta Oncol. 2022 Sep;61(9):1157-1161. doi: 10.1080/0284186X.2022.2127121. Epub 2022 Sep 29.
2
Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.分析真实世界数据，探究种族和民族对晚期非小细胞肺癌患者程序性细胞死亡受体 1 和程序性细胞死亡配体 1 抑制剂应答的影响。
Oncologist. 2021 Jul;26(7):e1226-e1239. doi: 10.1002/onco.13780. Epub 2021 May 11.
3
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).程序性细胞死亡蛋白-1（PD-1）抑制剂联合抗血管生成靶向药物作为晚期或转移性非小细胞肺癌（NSCLC）后续治疗的疗效和安全性。
Thorac Cancer. 2021 Sep;12(17):2360-2368. doi: 10.1111/1759-7714.14078. Epub 2021 Jul 16.
4
Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway.现实世界中接受免疫检查点抑制剂治疗的非小细胞肺癌患者的特征与生存情况：来自挪威卑尔根的经验
Acta Oncol. 2022 Jul;61(7):814-818. doi: 10.1080/0284186X.2022.2068969. Epub 2022 Apr 28.
5
Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.阿替利珠单抗治疗非小细胞肺癌的真实世界疗效：一项针对体能状态和抗 PD-1 抗体治疗失败后再次治疗的多中心队列研究。
Thorac Cancer. 2021 Mar;12(5):613-618. doi: 10.1111/1759-7714.13824. Epub 2021 Jan 15.
6
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.既往胸部放疗对晚期非小细胞肺癌免疫检查点抑制剂疗效的影响。
Jpn J Clin Oncol. 2021 Feb 8;51(2):279-286. doi: 10.1093/jjco/hyaa180.
7
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.一项评估 PD-L1 高 KRAS 突变型一线免疫检查点抑制剂治疗的晚期非小细胞肺癌（NSCLC）患者结局的单机构研究。
Cancer Treat Res Commun. 2021;27:100330. doi: 10.1016/j.ctarc.2021.100330. Epub 2021 Feb 6.
8
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.晚期非小细胞肺癌患者中抗 PD-1 和抗 PD-L1 抗体免疫检查点抑制剂再挑战时的给药切换：病例系列和文献复习。
Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.
9
Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.免疫检查点抑制剂治疗晚期非小细胞肺癌后安全性事件的发生率：一项真实世界研究。
Future Oncol. 2022 Aug;18(26):2891-2901. doi: 10.2217/fon-2022-0308. Epub 2022 Jul 18.
10
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.用于有特殊问题的非小细胞肺癌患者的程序性死亡受体1抑制剂：真实世界证据
Cancer Med. 2020 Apr;9(7):2352-2362. doi: 10.1002/cam4.2868. Epub 2020 Feb 6.

引用本文的文献

1
Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review.度伐利尤单抗联合卡铂-依托泊苷治疗一名接受血液透析的小细胞肺癌患者：病例报告及文献综述
Int Cancer Conf J. 2023 Dec 21;13(2):88-92. doi: 10.1007/s13691-023-00640-8. eCollection 2024 Apr.
2
Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series.贝伐珠单抗联合阿替利珠单抗治疗不可切除肝细胞癌透析患者的安全性和有效性：病例系列研究。
Clin J Gastroenterol. 2024 Jun;17(3):515-522. doi: 10.1007/s12328-024-01946-7. Epub 2024 Mar 19.
3
Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab.
病例报告：使用阿替利珠单抗和贝伐单抗成功治疗一名患有多灶性肝细胞癌的血液透析患者。
Front Oncol. 2024 Jan 4;13:1279501. doi: 10.3389/fonc.2023.1279501. eCollection 2023.
4
Successful treatment with atezolizumab in a haemodialysis patient with large cell neuroendocrine carcinoma.阿特珠单抗成功治疗一名患有大细胞神经内分泌癌的血液透析患者。
Respirol Case Rep. 2023 Jul 19;11(8):e01193. doi: 10.1002/rcr2.1193. eCollection 2023 Aug.